title: Estimation of renal function and its potential impact on carboplatin dosing in children with cancer.
abstract: Renal function-based carboplatin dosing is used routinely in paediatric oncology clinical practice. It is important that accurate assessments of renal function are carried out consistently across clinical centres, a view supported by recently published British Nuclear Medicine Society (BNMS) guidelines for measuring glomerular filtration rate (GFR). These guidelines recommend the use of a radioisotope method for GFR determination, with between two and five blood samples taken starting 2 h after radioisotope injection and application of the Brochner-Mortensen (BM) correction factor. To study the likely impact of these guidelines, we have investigated current practices of measuring GFR in all 21 Children's Cancer and Leukaemia Group (CCLG) paediatric oncology centres in the United Kingdom. This information was used to evaluate the potential impact on renal function-based carboplatin dosing using raw 51Cr-EDTA clearance data from 337 GFR tests carried out in children with cancer. A questionnaire survey revealed that between two and four samples were taken after isotope administration, with BM and Chantler corrections used in 38% (8/21) and 28% (6/21) of centres, respectively. A change from Chantler to BM correction, based on the BNMS guidelines, would result in a > 10% decrease in carboplatin dose in at least 15% of patients and a > 25% decrease in 2% of patients. A greater proportion of patients would have an alteration in carboplatin dose when centres not using any correction factor implement the BM correction. The increase in estimated 51Cr-EDTA half-life observed by omitting the I h sample decreases carboplatin dose by > 10% in 23-52% of patients and by > 25% in 3% of patients. This study highlights current variations in renal function measurement between clinical centres and the potential impact on carboplatin dosing. A standard methodology for estimating GFR should be followed to achieve uniform dosing in children with cancer.
authors.affiliation: Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne NE2 4HH, UK.
authors.forename: G
authors.initials: G
authors.lastname: Chinnaswamy
authors.forename: M
authors.initials: M
authors.lastname: Cole
authors.forename: A V
authors.initials: AV
authors.lastname: Boddy
authors.forename: M
authors.initials: M
authors.lastname: Keir
authors.forename: L
authors.initials: L
authors.lastname: Price
authors.forename: A
authors.initials: A
authors.lastname: Parry
authors.forename: M
authors.initials: M
authors.lastname: English
authors.forename: G J
authors.initials: GJ
authors.lastname: Veal
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000493:pharmacokinetics; D005919:Glomerular Filtration Rate; D006801:Humans; D007223:Infant; D007668:Kidney / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D011866:Radioisotope Renography / Q000592:standards* / Q000706:statistics & numerical data; D012189:Retrospective Studies; D011795:Surveys and Questionnaires; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; C477055:aqua(edetic acid)chromium(III); D004492:Edetic Acid; D016190:Carboplatin
references.citation: Scand J Clin Lab Invest. 1972 Nov;30(3):271-4
references.pmid: 4629674
references.citation: Scand J Clin Lab Invest. 1974 Apr;33(2):140-3
references.pmid: 4211765
references.citation: J Nucl Med. 1966 Jan;7(1):60-8
references.pmid: 5907195
references.citation: Br J Radiol. 1976 Sep;49(585):794-6
references.pmid: 822911
references.citation: Clin Sci (Lond). 1984 May;66(5):613-9
references.pmid: 6423339
references.citation: J Clin Oncol. 2000 Nov 1;18(21):3614-21
references.pmid: 11054434
references.citation: Pediatr Nephrol. 2002 Nov;17(11):903-7
references.pmid: 12432431
references.citation: Arch Dis Child. 1972 Aug;47(254):613-7
references.pmid: 4625784
references.citation: J Clin Oncol. 1989 Nov;7(11):1748-56
references.pmid: 2681557
references.citation: Br J Cancer. 2004 Jan 12;90(1):60-4
references.pmid: 14710207
references.citation: Arch Dis Child. 2000 Jan;82(1):71-5
references.pmid: 10630919
references.citation: Nucl Med Commun. 2004 Aug;25(8):759-69
references.pmid: 15266169
references.citation: Pediatr Nephrol. 2006 Dec;21(12):1865-72
references.pmid: 17013606
references.citation: Eur J Nucl Med. 1985;11(1):7-12
references.pmid: 3899658
references.citation: Pediatrics. 1976 Aug;58(2):259-63
references.pmid: 951142
references.citation: Eur J Nucl Med. 1992;19(1):30-5
references.pmid: 1547805
references.citation: J Clin Oncol. 1993 Dec;11(12):2314-23
references.pmid: 8246021
references.citation: Clin Chim Acta. 2000 Jul;297(1-2):55-66
references.pmid: 10841908
references.citation: J Cancer Res Clin Oncol. 2005 Sep;131(9):559-67
references.pmid: 16012866
references.citation: Br J Cancer. 2001 Feb;84(4):452-9
references.pmid: 11207037
references.citation: J Pediatr Hematol Oncol. 2003 Oct;25(10):818-21
references.pmid: 14528109